Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

Neuroinflammation in Alzheimer's disease

Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · see citing works

2016 Alzheimer's disease facts and figures

Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works

The molecular pathology of Alzheimer's disease

Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708 · see citing works

Molecular dissection of reactive astrogliosis and glial scar formation

Sofroniew, M. V. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.08.002 · Cited by 2,594 · see citing works

Amyloid deposition as the central event in the aetiology of Alzheimer’s disease

Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · see citing works

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works

2015 Alzheimer's disease facts and figures

Alzheimer's Association (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,641 · see citing works

The Mystery and Magic of Glia: A Perspective on Their Roles in Health and Disease

Barres, B. A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.013 · Cited by 1,352 · see citing works

Alzheimer’s disease: Clinical trials and drug development

Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works

2012 Alzheimer's disease facts and figures Alzheimer's Association ∗

Thies, W. H., & Bleiler, L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 984 · see citing works

GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease

Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3639 · Cited by 783 · see citing works

Alzheimer's disease drug development pipeline: 2018

Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works

DT‐01‐04: The efficacy of RVT‐101, a 5‐ht6 receptor antagonist, as an adjunct to donepezil in adults with mild‐to‐moderate Alzheimer's disease: Completer analysis of a phase 2b study

Lombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. T. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

Alzheimer's disease drug development pipeline: 2017

Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · see citing works

Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B

Colibus, L. D., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505975102 · Cited by 536 · see citing works

Update on Alzheimer’s Disease Therapy and Prevention Strategies

Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506 · see citing works

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382 · see citing works

P1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort

Burnham, S. C., Graham, P. L., Wilson, B., Ames, D. J., Macaulay, L. S., Martins, R. N., Masters, C. L., Maruff, P. T., Rowe, C. C., Szoeke, C. E. I., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.347 · Cited by 292 · see citing works

Implications of GABAergic Neurotransmission in Alzheimer’s Disease

Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., & Zheng, H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00031 · Cited by 274 · see citing works

Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels

Schedin‐Weiss, S., Inoue, M., Hromádková, L., Teranishi, Y., Yamamoto, N. G., Wiehager, B., Bogdanović, N., Winblad, B. G., Matton, A., Frykman, S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0279-1 · Cited by 237 · see citing works

Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons

Kim, J.-I., Ganesan, S., Luo, S. X., Wu, Y.-W., Park, E., Huang, E. J., Chen, L., & Ding, J. B. (2015) · Science · doi:10.1126/science.aac4690 · Cited by 217 · see citing works

Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition

Yoon, B., Woo, J., Chun, Y. E., Chun, H., Jo, S., Bae, J. Y., An, H., Min, J.-O., Oh, S., Han, K., et al. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.278754 · Cited by 178 · see citing works

Effects of a MAO-B Inhibitor in the Treatment of Alzheimer Disease

Mangoni, A. A., Grassi, M. P., Frattola, L., Piolti, R., Bassi, S., Motta, A., Marcone, A., & Smirne, S. (2008) · European Neurology · doi:10.1159/000116655 · Cited by 150 · see citing works

A disulphide-linked heterodimer of TWIK-1 and TREK-1 mediates passive conductance in astrocytes

Hwang, E. M., Kim, E., Yarishkin, O. V., Woo, D. H., Han, K., Park, N., Bae, Y., Woo, J., Kim, D.-G., Park, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4227 · Cited by 149 · see citing works

Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal

Fowler, J. S., Volkow, N. D., Logan, J., Wang, G., Gregor, R. R. M., Schlyer, D. J., Wolf, A. P., Pappas, N. R., Alexoff, D. L., Shea, C. E., et al. (1994) · Synapse · doi:10.1002/syn.890180203 · Cited by 147 · see citing works

Neuropsychological Effects of L-Deprenyl in Alzheimerʼs Type Dementia

Piccinin, G. L., Finali, G., & Piccirilli, M. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199004000-00004 · Cited by 115 · see citing works

Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity

Marzo, A. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.004 · Cited by 109 · see citing works

Phosphorylation by PINK1 Releases the UBL Domain and Initializes the Conformational Opening of the E3 Ubiquitin Ligase Parkin

Caulfield, T. R., Fiesel, F. C., Moussaud-Lamodière, E. L., Dourado, D. F. A. R., Flores, S. C., & Springer, W. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003935 · Cited by 108 · see citing works

Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors

Choi, J. W., Jang, B. K., Cho, N., Park, J., Yeon, S. K., Ju, E. J., Lee, Y. S., Han, G., Pae, A. N., Kim, D. J., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.012 · Cited by 90 · see citing works

Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease

Nam, M., Park, M., Park, H., Kim, Y., Yoon, S.-K., Sawant, V. S., Choi, J. W., Park, J., Park, K. D., Min, S., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00050 · Cited by 67 · see citing works

The effect of selegiline in the treatment of people with Alzheimer's disease: a meta‐analysis of published trials

Wilcock, G. K., Birks, J., Whitehead, A., & Evans, S. J. G. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.545 · Cited by 59 · see citing works

The Failure of Solanezumab — How the FDA Saved Taxpayers Billions

Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1701047 · Cited by 55 · see citing works

Activation of the E3 ubiquitin ligase Parkin

Caulfield, T. R., Fiesel, F. C., & Springer, W. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140321 · Cited by 50 · see citing works

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)

Navé, S., Doody, R. S., Boada, M., Grimmer, T., Savola, J., Delmar, P., Pauly-Evers, M., Nikolcheva, T., Czech, C., Borroni, E., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161309 · Cited by 48 · see citing works

Characteristics of putrescine uptake and subsequent GABA formation in primary cultured astrocytes from normal C57BL/6J and epileptic DBA/2J mouse brain cortices

Laschet, J. J., Grisar, T. M., Bureau, M., & Guillaume, D. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90345-3 · Cited by 40 · see citing works

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31 · see citing works

GABA and its relationship to putrescine metabolism in the rat brain and pancreas

Caron, P. C., Kremzner, L. T., & COTE, L. J. (1987) · Neurochemistry International · doi:10.1016/0197-0186(87)90131-8 · Cited by 28 · see citing works

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

Froestl, W., Muhs, A., & Pfeifer, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140402 · Cited by 23 · see citing works

Evidence that l-deprenyl treatment for one week does not inhibit mao a or the dopamine transporter in the human brain

Fowler, J. S., Volkow, N. D., Logan, J., Franceschi, D., Wang, G., MacGregor, R. R., Shea, C. E., Garza, V., Pappas, N. R., Carter, P., et al. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01079-7 · Cited by 23 · see citing works

Phase 3 Trials of Solanezumab for Mild-To-Moderate Alzheimer's Disease

(2014) · New England Journal of Medicine · doi:10.1056/nejmx140041 · Cited by 18 · see citing works

Reactive astrocyte nomenclature, definitions, and future directions

Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Agarwal, A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00783-4 · Cited by 2,533 · see citing works

Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors

Behl, T., Kaur, D., Sehgal, A., Singh, S., Sharma, N., Zengin, G., Andronie-Cioară, F. L., Toma, M. M., BUNGAU, S. G., & Bumbu, A. G. (2021) · Molecules · doi:10.3390/molecules26123724 · Cited by 333 · see citing works

Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2− production

Chun, H., Im, H., Kang, Y. J., Kim, Y., Shin, J. H., Won, W., Lim, J., Ju, Y. H., Park, Y. M., Kim, S., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00735-y · Cited by 274 · see citing works

A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review

Manzoor, S., & Hoda, N. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112787 · Cited by 264 · see citing works

GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease

Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12088 · Cited by 232 · see citing works

Interactions of glial cells with neuronal synapses, from astrocytes to microglia and oligodendrocyte lineage cells

Liu, Y., Shen, X. P., Zhang, Y., Zheng, X., Cepeda, C., Wang, Y., Duan, S., & Tong, X. (2023) · Glia · doi:10.1002/glia.24343 · Cited by 190 · see citing works

Polyamines: their significance for maintaining health and contributing to diseases

Xuan, M., Gu, X., Li, J., Huang, D., Chen, X., & He, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01373-0 · Cited by 159 · see citing works

Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease

Arbo, B. D., André‐Miral, C., Nasre‐Nasser, R. G., Schimith, L. E., dos Santos, M. G., da Costa-Silva, D. G., Muccillo-Baisch, A. L., & Hort, M. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00103 · Cited by 156 · see citing works

Astrocytes Control Sensory Acuity via Tonic Inhibition in the Thalamus

Kwak, H., Koh, W., Kim, S., Song, K., Shin, J.-I., Lee, J. M., Lee, E. H., Bae, J. Y., Ha, G. E., Oh, J.-E., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.013 · Cited by 150 · see citing works

Astrocytic urea cycle detoxifies Aβ-derived ammonia while impairing memory in Alzheimer’s disease

Ju, Y. H., Bhalla, M., Hyeon, S. J., Oh, J. E., Yoo, S., Chae, U., Kwon, J., Koh, W., Lim, J., Park, Y. M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.011 · Cited by 145 · see citing works

Redefining differential roles of MAO-A in dopamine degradation and MAO-B in tonic GABA synthesis

Cho, H., Kim, S., Sim, J., Yang, S., An, H., Nam, M., Jang, D. P., & Lee, C. J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00646-3 · Cited by 142 · see citing works

Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease

Heo, J. Y., Nam, M.-H., Yoon, H. H., Kim, J., Hwang, Y. J., Won, W., Woo, D. H., Lee, J. A., Park, H.-J., Jo, S., et al. (2020) · Current Biology · doi:10.1016/j.cub.2019.11.079 · Cited by 135 · see citing works

Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease

Kim, S., Chun, H., Kim, Y., Kim, Y., Park, U., Chu, J., Bhalla, M., Choi, S.-H., Yousefian-Jazi, A., Kim, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00740-w · Cited by 126 · see citing works

Astrocytes: GABAceptive and GABAergic Cells in the Brain

Liu, J., Feng, X., Wang, Y., Xia, X., & Zheng, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.892497 · Cited by 81 · see citing works

Astrocyte regulation of synaptic signaling in psychiatric disorders

Kruyer, A., Kalivas, P. W., & Scofield, M. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01338-w · Cited by 76 · see citing works

Diverse Actions of Astrocytes in GABAergic Signaling

Ishibashi, M., Egawa, K., & Fukuda, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122964 · Cited by 75 · see citing works

Astrocytes as Key Regulators of Neural Signaling in Health and Disease

Won, W., Bhalla, M., Lee, J., & Lee, C. J. (2025) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-035356 · Cited by 74 · see citing works

Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke

Nam, M., Cho, J., Kwon, D.-H., Park, J., Woo, J., Lee, J. M., Lee, S., Ko, H. Y., Won, W., Kim, R. G., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107861 · Cited by 73 · see citing works

Reactive astrocytes as treatment targets in Alzheimer's disease—Systematic review of studies using the <scp>APPswePS1dE9</scp> mouse model

Smit, T., Deshayes, N. A. C., Borchelt, D. R., Kamphuis, W., Middeldorp, J., & Hol, E. M. (2021) · Glia · doi:10.1002/glia.23981 · Cited by 71 · see citing works

Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease

Zhang, C., Yang, K., Yu, S., Su, J., Yuan, S., Han, J., Chen, Y., Gu, J., Zhou, T., Bai, R., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.031 · Cited by 70 · see citing works

Visualizing reactive astrocyte-neuron interaction in Alzheimer’s disease using 11C-acetate and 18F-FDG

Nam, M., Ko, H. Y., Kim, D., Lee, S., Park, Y. M., Hyeon, S. J., Won, W., Chung, J.-I., Kim, S. Y., Jo, H. H., et al. (2023) · Brain · doi:10.1093/brain/awad037 · Cited by 69 · see citing works

Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease

Choi, M., Kim, H.-J., Yang, E.-J., & Kim, H.-S. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.05.009 · Cited by 69 · see citing works

Revisiting the Role of Astrocytic MAOB in Parkinson’s Disease

Nam, M., Sa, M., Ju, Y. H., Park, M. G., & Lee, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084453 · Cited by 68 · see citing works

Emotional and cognitive changes in chronic kidney disease

Kim, D., Kim, S.-W., & Gil, H. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.492 · Cited by 67 · see citing works

GABA release from astrocytes in health and disease.

Kilb, W., & Kirischuk, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415859 · Cited by 66 · see citing works

An Expanded Narrative Review of Neurotransmitters on Alzheimer’s Disease: The Role of Therapeutic Interventions on Neurotransmission

Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69 · see citing works

Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents

Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 61 · see citing works

Progress in Target Drug Molecules for Alzheimer's Disease

Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 57 · see citing works

Advances in Amyloid-β Clearance in the Brain and Periphery: Implications for Neurodegenerative Diseases

Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 49 · see citing works

Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches

Duarte, P., Cuadrado, A., & Leon, R. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_384 · Cited by 49 · see citing works

Structure-Based Design of Novel MAO-B Inhibitors: A Review

Mateev, E., Georgieva, M., Mateeva, A., Zlatkov, A., Ahmad, S., Raza, K., Azevedo, V., & Barh, D. (2023) · Molecules · doi:10.3390/molecules28124814 · Cited by 47 · see citing works

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease

Nam, M., Park, J., Song, H. J., Choi, J., Kim, S., Jang, B. K., Yoon, H. H., Heo, J. Y., Lee, H., An, H., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01097-4 · Cited by 47 · see citing works

8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases

Knez, D., Diez‐Iriepa, D., Chioua, M., Gottinger, A., Denic, M., Chantegreil, F., Nachon, F., Brazzolotto, X., Skrzypczak-Wiercioch, A., Meden, A., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.013 · Cited by 46 · see citing works

Pyrimido[1,2-b]indazole derivatives: Selective inhibitors of human monoamine oxidase B with neuroprotective activity

Jismy, B., Qami, A. E., Pišlar, A. H., Frlan, R., Kos, J., Gobec, S., Knez, D., & Abarbri, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112911 · Cited by 45 · see citing works

Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands

Rodríguez‐Soacha, D. A., Scheiner, M., & Decker, M. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.040 · Cited by 44 · see citing works

Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA

Sa, M., Yoo, E.-S., Koh, W., Park, M. G., Jang, H., Yang, Y. R., Bhalla, M., Lee, J., Lim, J., Won, W., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00877-w · Cited by 43 · see citing works

Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity

D’Acunzo, P., Argyrousi, E. K., Ungania, J. M., Kim, Y., DeRosa, S., Pawlik, M., Goulbourne, C. N., Arancio, O., & Levy, E. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00721-z · Cited by 42 · see citing works

Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model

Chun, H., Lim, J., Park, K. D., & Lee, C. J. (2021) · Glia · doi:10.1002/glia.24110 · Cited by 42 · see citing works

20(S)-protopanaxadiol and oleanolic acid ameliorate cognitive deficits in APP/PS1 transgenic mice by enhancing hippocampal neurogenesis

Lin, K., Sze, S. C. W., Liu, B., Zhang, Z., Zhang, Z., Zhu, P., Wang, Y., Deng, Q., Yung, K. K. L., & Zhang, S. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.07.003 · Cited by 41 · see citing works

Monoamine oxidase and neurodegeneration: Mechanisms, inhibitors and natural compounds for therapeutic intervention

Banerjee, C., Tripathy, D., Kumar, D., & Chakraborty, J. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105831 · Cited by 40 · see citing works

Targeting Biometals in Alzheimer’s Disease with Metal Chelating Agents Including Coumarin Derivatives

Gucký, A., & Hamuľaková, S. (2024) · CNS Drugs · doi:10.1007/s40263-024-01093-0 · Cited by 39 · see citing works

Monoamine oxidase B inhibitors based on natural privileged scaffolds: A review of systematically structural modification

Lv, Y., Zheng, Z., Liu, R., Guo, J., Zhang, C., & Xie, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126158 · Cited by 37 · see citing works

Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine

Matveychuk, D., MacKenzie, E. M., Kumpula, D. J., Song, M.-S., Holt, A., Kar, S., Todd, K. G., Wood, P. L., & Baker, G. B. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01078-3 · Cited by 37 · see citing works

Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine- and Rotenone-Induced Oxidative Stress

Elsherbeny, M. H., Kim, J., Gouda, N. A., Gotina, L., Cho, J., Pae, A. N., Lee, K., Park, K. D., Elkamhawy, A., & Roh, E. J. (2021) · Antioxidants · doi:10.3390/antiox10101641 · Cited by 37 · see citing works

Adenovirus-induced Reactive Astrogliosis Exacerbates the Pathology of Parkinson’s Disease

An, H., Lee, H., Yang, S., Won, W., Lee, C. J., & Nam, M. (2021) · Experimental Neurobiology · doi:10.5607/en21013 · Cited by 35 · see citing works

A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement

Li, Q., Xiong, B., Wang, Y., Lyu, W., Xing, S., Chen, Y., Liao, Q., He, S., Feng, F., Liu, W., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114510 · Cited by 35 · see citing works

Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis

Won, W., Choi, H., Yoo, J., Kim, D., Kim, T. Y., Ju, Y. H., Park, K. D., Lee, H., Jung, Y., & Lee, C. J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00830-z · Cited by 35 · see citing works

Polygonatum sibiricum ameliorated cognitive impairment of naturally aging rats through BDNF–TrkB signaling pathway

Zhang, X., Ni, L., Hu, S., Yue, B., Chen, X., Yuan, D., Wang, T., & Zhou, Z. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14510 · Cited by 35 · see citing works

The hippocampus associated GABAergic neural network impairment in early-stage of Alzheimer's disease

Tang, Y., Yan, Y., Mao, J., Ni, J., & Qing, H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101865 · Cited by 34 · see citing works

Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors

El‐Damasy, A. K., Park, J., Kim, H. J., Lee, J., Bang, E., Kim, H., & Keum, G. (2023) · Pharmaceuticals · doi:10.3390/ph16010083 · Cited by 33 · see citing works

Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies

Wasan, H., Singh, D., & Kh, R. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.018 · Cited by 33 · see citing works

A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer’s Disease

Lee, S. Y., Song, M.-Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01653 · Cited by 32 · see citing works

Possible neuroprotective effects of amide alkaloids from <i>Bassia indica</i> and <i>Agathophora alopecuroides</i> : <i>in vitro</i> and <i>in silico</i> investigations

Othman, A., Sayed, A. M., Amen, Y., & Shimizu, K. (2022) · RSC Advances · doi:10.1039/d2ra02275c · Cited by 32 · see citing works

Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of 1H-indazole-bearing neuroprotective MAO B inhibitors

Rullo, M., Spada, G. L., Miniero, D. V., Gottinger, A., Catto, M., Delre, P., Mastromarino, M., Latronico, T., Marchese, S., Mangiatordi, G. F., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115352 · Cited by 31 · see citing works

Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications

Prà, I. D., Armato, U., & Chiarini, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01282 · Cited by 31 · see citing works

New Insights on the Activity and Selectivity of MAO-B Inhibitors through In Silico Methods

Pacureanu, L. M., Bora, A., & Crisan, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119583 · Cited by 30 · see citing works

Application of biomarker-derived fluorescent probes for the detection of Alzheimer's disease

Ding, H., Li, Z., Luo, K., Gong, Q., & Tian, X. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117369 · Cited by 30 · see citing works

Neuroglia in cognitive reserve

Verkhratsky, A., & Zorec, R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02644-z · Cited by 30 · see citing works

Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection

Čuperlović‐Culf, M., Cunningham, E. L., Teimoorinia, H., Surendra, A., Pan, X., Bennett, S. A. L., Jung, M., McGuiness, B., Passmore, A. P., Beverland, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90243-1 · Cited by 30 · see citing works

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases

Mannan, A., Singh, T. G., Singh, V., Garg, N., Kaur, A., & Singh, M. (2021) · Current Drug Targets · doi:10.2174/1389450122666210707120256 · Cited by 30 · see citing works

A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties

Canale, V., Grychowska, K., Kurczab, R., Ryng, M., Keeri, A. R., Satała, G., Olejarz‐Maciej, A., Koczurkiewicz, P., Drop, M., Blicharz-Futera, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112765 · Cited by 28 · see citing works

KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease

Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27 · see citing works

DAla2-GIP-GLU-PAL Protects Against Cognitive Deficits and Pathology in APP/PS1 Mice by Inhibiting Neuroinflammation and Upregulating cAMP/PKA/CREB Signaling Pathways

Yuan, L., Zhang, J., Guo, J., Hölscher, C., Yang, J., Wu, M., Wang, Z.-J., Cai, H.-Y., Han, L., Shi, H., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201262 · Cited by 27 · see citing works

Synthesis and identification of a novel derivative of salidroside as a selective, competitive inhibitor of monoamine oxidase B with enhanced neuroprotective properties

Yang, Z., Huang, X., Lai, W., Tang, Y., Liu, J., Wang, Y., Chu, K., Brown, J., & Hong, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112935 · Cited by 27 · see citing works

Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine

Tao, C., Hu, S.-Q., Chen, J., Chen, Y.-J., Sun, K., Cui, G., Ma, M., & Wu, Z. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104807 · Cited by 26 · see citing works

Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer’s Treatment: A Computational Strategy

Jabir, N. R., Rehman, M. T., Tabrez, S. S. M., Alserihi, R. F., Alajmi, M. F., Khan, M. S., Husain, F. M., & Ahmed, A. B. A. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210226123240 · Cited by 26 · see citing works

Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases

Hassan, A. H. E., Kim, H. J., Gee, M. S., Park, J., Jeon, H. R., Lee, C. J., Choi, Y., Moon, S., Lee, D., Lee, J. K., et al. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2036737 · Cited by 26 · see citing works

Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank

Pinzi, L., & Rastelli, G. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00821 · Cited by 25 · see citing works

The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB

An, H., Heo, J. Y., Lee, C. J., & Nam, M. (2021) · Experimental Neurobiology · doi:10.5607/en21007 · Cited by 25 · see citing works

Chasing ChEs-MAO B Multi-Targeting 4-Aminomethyl-7-Benzyloxy-2H-Chromen-2-ones

Rullo, M., Catto, M., Carrieri, A., de Candia, M., Altomare, C., & Pisani, L. (2019) · Molecules · doi:10.3390/molecules24244507 · Cited by 25 · see citing works

Tonic excitation by astrocytic GABA causes neuropathic pain by augmenting neuronal activity and glucose metabolism

Ju, Y. H., Cho, J., Park, J., Kim, H., Hong, E.-B., Park, K. D., Lee, C. J., Chung, E., Kim, H.-I., & Nam, M. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01232-z · Cited by 24 · see citing works

Longitudinal intravital imaging of cerebral microinfarction reveals a dynamic astrocyte reaction leading to glial scar formation

Lee, J., Kim, J., Hong, S., Kim, Y. S., Ahn, S., Kim, R., Chun, H., Park, K. D., Jeong, Y., Kim, D., et al. (2022) · Glia · doi:10.1002/glia.24151 · Cited by 24 · see citing works

How “Neuronal” Are Human Skin Mast Cells?

Babina, M., Franke, K., & Bal, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810871 · Cited by 24 · see citing works

The involvement of the mitochondrial membrane in drug delivery

Huang, Y., Ji, W., Zhang, J., Huang, Z. H., Ding, A., Bai, H., Peng, B., Huang, K., Du, W., Zhao, T., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.027 · Cited by 24 · see citing works

Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

Herrera‐Arozamena, C., Estrada, M., López‐Caballero, P., Pérez, C., Morales-Garcia, J. A., Pérez‐Castillo, A., del Sastre, E., Fernández‐Mendívil, C., Duarte, P., Michalska, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01883 · Cited by 24 · see citing works

SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer’s disease

Bhalla, M., Joo, J., Kim, D., Shin, J. I., Park, Y. M., Ju, Y. H., Park, U., Yoo, S., Hyeon, S. J., Lee, H., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00788-8 · Cited by 23 · see citing works

A monoamine oxidase B inhibitor ethyl ferulate suppresses microglia-mediated neuroinflammation and alleviates ischemic brain injury

Zou, X., Gao, S., Li, J., Li, C., Wu, C., Cao, X., Xia, S., Shao, P., Bao, X., Yang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1004215 · Cited by 23 · see citing works

Magnetic chitosan hydrogel induces neuronal differentiation of neural stem cells by activating RAS-dependent signal cascade

Zhang, J., Wang, Y., Shu, X., Deng, H., Wu, F., & He, J. H. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120918 · Cited by 23 · see citing works

Nature as a source and inspiration for human monoamine oxidase B (hMAO-B) inhibition: A review of the recent advances in chemical modification of natural compounds

Melfi, F., Carradori, S., Angeli, A., & D’Agostino, I. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2226860 · Cited by 22 · see citing works

The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD

Park, H., Han, K., Jeon, H., Lee, J.-S., Lee, H., Jeon, S. G., Park, J.-H., Kim, Y. G., Lin, Y., Lee, Y., et al. (2020) · Cells · doi:10.3390/cells9091982 · Cited by 22 · see citing works

Mapping Chromone-3-Phenylcarboxamide Pharmacophore: Quid Est Veritas?

Mesiti, F., Gaspar, A., Chavarria, D., Maruca, A., Rocca, R., Gil-Martins, E., Barreiro, S., Silva, R., Fernandes, C., Gul, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00510 · Cited by 22 · see citing works

Astrocyte modulation in cerebral ischemia-reperfusion injury: A promising therapeutic strategy

Wang, Z., Zhang, X., Zhang, G., Zheng, Y. J., Zhao, A., Jiang, X., & Gan, J. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114814 · Cited by 21 · see citing works

New 1,2,4-oxadiazole derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease: design, synthesis, and biological evaluation

Ayoup, M. S., Ghanem, M., Abdel‐Hamid, H., Abu-Serie, M. M., Masoud, A. A., Ghareeb, D. A., Hawsawi, M. B., Sonousi, A. S. M., & Kassab, A. E. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01235-x · Cited by 21 · see citing works

Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease

Godyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21 · see citing works

A Key Mediator and Imaging Target in Alzheimer’s Disease: Unlocking the Role of Reactive Astrogliosis Through MAOB

Nam, M.-H., Na, H., Lee, C. J., & Yun, M. (2024) · Nuclear medicine and molecular imaging · doi:10.1007/s13139-023-00837-y · Cited by 21 · see citing works

Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1 H-pyrrolo-[3,2-c]quinolines

Grychowska, K., Olejarz‐Maciej, A., Blicharz-Futera, K., Pietruś, W., Karcz, T. P., Kurczab, R., Koczurkiewicz, P., Doroż-Płonka, A., Latacz, G., Keeri, A. R., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114329 · Cited by 19 · see citing works

Alzheimer's disease

Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 18 · see citing works

Generation of Astrocyte-Specific MAOB Conditional Knockout Mouse with Minimal Tonic GABA Inhibition

Lee, J. M., Sa, M., An, H., Kim, J. M. J., Kwon, J., Yoon, B., & Lee, C. J. (2022) · Experimental Neurobiology · doi:10.5607/en22016 · Cited by 18 · see citing works

Printed Electronics in Radiofrequency Energy Harvesters and Wireless Power Transfer Rectennas for IoT Applications

Skarżyński, K., & Słoma, M. (2023) · Advanced Electronic Materials · doi:10.1002/aelm.202300238 · Cited by 18 · see citing works

Baicalin and baicalein from Scutellaria baicalensis Georgi alleviate aberrant neuronal suppression mediated by GABA from reactive astrocytes

Cho, J., Hong, E., Kim, Y., Song, J., Ju, Y. H., Kim, H., Lee, H., Kim, H., & Nam, M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14740 · Cited by 18 · see citing works

Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease

Kong, Y., Maschio, C., Shi, X., Yao, B., Xie, F., Zuo, C., Konietzko, U., Shi, K., Rominger, A., Xiao, J., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04106-7 · Cited by 17 · see citing works

Rhythmic astrocytic GABA production synchronizes neuronal circadian timekeeping in the suprachiasmatic nucleus

Ness, N., Díaz-Clavero, S., Hoekstra, M. M., & Brancaccio, M. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00324-w · Cited by 17 · see citing works

Molecular pathways: the quest for effective MAO-B inhibitors in neurodegenerative therapy

Oyovwi, M. O., Udi, O. A., Atere, A. D., Joseph, G. U., & Godsday, O. U. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10349-x · Cited by 17 · see citing works

Systemic Immune Dyshomeostasis Model and Pathways in Alzheimer’s Disease

Talwar, P., Kushwaha, S. S., Gupta, R., & Agarwal, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00290 · Cited by 17 · see citing works

Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model

Park, S. E., Neupane, C., Noh, C., Sharma, R., Shin, H. J., Phạm, T. L., Lee, G., Park, K. D., Lee, C. J., Kang, D.-W., et al. (2022) · Molecular Brain · doi:10.1186/s13041-022-00924-9 · Cited by 17 · see citing works

The Role of the Urea Cycle in the Alzheimer's Disease Brain

Al‐Thani, N. A., Stewart, G. S., & Costello, D. A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70033 · Cited by 16 · see citing works

Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases

Won, W., Lee, E. H., Gotina, L., Chun, H., Lee, J., Bhalla, M., Park, U., Kim, D., Kim, T. Y., Choi, J. W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02366-w · Cited by 16 · see citing works

Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies

Elkamhawy, A., Paik, S., Park, J., Kim, H. J., Hassan, A. H. E., Lee, K., Park, K. D., & Roh, E. J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105233 · Cited by 16 · see citing works

MAO-B Inhibitor, KDS2010, Alleviates Spinal Nerve Ligation-induced Neuropathic Pain in Rats Through Competitively Blocking the BDNF/TrkB/NR2B Signaling

Phạm, T. L., Noh, C., Neupane, C., Sharma, R., Shin, H. J., Park, K. D., Lee, C. J., Kim, H., Lee, S. Y., & Park, J. B. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.07.010 · Cited by 16 · see citing works

Astrocyte strategies in the energy-efficient brain

Fernández-González, I., & Galea, E. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220077 · Cited by 16 · see citing works

KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease

Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27 · see citing works

P1‐075: Development of a Novel Inhibitor of Aberrant Gaba Synthesis in Reactive Astrocytes for Treatment of Alzheimer’s Disease

Park, J., & Park, K. D. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.823

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease

Nam, M., Park, J., Song, H. J., Choi, J., Kim, S., Jang, B. K., Yoon, H. H., Heo, J. Y., Lee, H., An, H., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01097-4 · Cited by 47 · see citing works

Reversible, selective inhibitors of MAO-A and -B

Kinemuchi, H., Toyoshima, Y., & Arai, Y. (1987) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)57991-4

2-(Phenylamino)-7,8-dihydroquinazolin-5(6H)-one, a promising scaffold for MAO-B inhibitors with potential GSK3β targeting

Paolo, M. L. D., Salerno, S., Nordio, G., Piazzola, F., Sarno, S., Sarno, G., Natale, B., Poggetti, V., Borreca, A., Baglini, E., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117580 · Cited by 3 · see citing works